Kura Oncology, Inc. 4

Chief Commercial Officer Brian T. Powl sold 4,345 shares of Kura Oncology, Inc. common stock at about $11.89 per share under a Rule 10b5-1 plan.

On August 21, 2026, Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl sold 4,345 shares of the company’s common stock at a weighted average price of approximately $11.89 per share, for total proceeds of about $51,700. The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 18, 2025, and was carried out in multiple trades within a price range of $11.78 to $12.00. Following this transaction, Powl’s direct ownership stood at 169,269 shares of Kura Oncology common stock, which, using the reported sale price as a proxy, represents an equity stake valued at roughly $2.0 million.

Filing Facts

CIK

1422143

Ticker

KURA

Form

4

Source Type

fda

Accession

0001193125-26-363810

Alert Tier

5